Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Vnitr Lek ; 55(11): I-XII, 2009 Nov.
Article in Czech | MEDLINE | ID: mdl-20017445

ABSTRACT

The registry of patients treated with Thromboreductin (anagrelide) in the Czech Republic contains data concerning patients that have been treated using this drug since 2004. As of June 2009, the total number of patients was 549. The current analysis focused mainly on evaluation of anagrelide dosage needed to achieve a complete response in high-risk patients: reduction in platelet count to below 400 x 10(9)/l, which was also considered as reaching the therapeutic goal. The outcomes of the registry confirm that although anagrelide (Thromboreductin) is a very effective platelet-reducing agent, the administration of which is related to a low incidence of adverse effects and complications, the therapeutic goal is not achieved in all cases and or despite a quick treatment response, the therapeutic goal is achieved more slowly.


Subject(s)
Myeloproliferative Disorders/complications , Platelet Aggregation Inhibitors/therapeutic use , Quinazolines/therapeutic use , Thrombocythemia, Essential/drug therapy , Thrombocytosis/drug therapy , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Thrombocytosis/complications
2.
Cas Lek Cesk ; 141(18): 575-7, 2002 Sep 13.
Article in Czech | MEDLINE | ID: mdl-12422567

ABSTRACT

BACKGROUND: Helicobacter (H.) pylori participates significantly on the pathogeny of chronic gastritis, duodenal a gastric ulcer, carcinoma and lymphoma of the stomach. Attention was attracted also by some extragastric diseases, including diabetes mellitus, where the elevated antibodies levels against H. pylori was found. The aim of the work was to determine the seroprevalence in relation to the sex and type of disease in a cohort of diabetics and in a control group of blood donors. METHODS AND RESULTS: In 195 diabetic patients (type I and II) and 216 blood donors levels of IgG antibodies were determined by ELISA method. Seroprevalence in the group of diabetic patients was 27%, in males 26% and in women 28% (n.s.). No differences related to sex or diabetes type were found. Significant differences in seroprevalence were found among the group of diabetic patients and blood donors (27% vs. 51%, p < 0.001), male diabetics of both types and blood donors (26% vs. 62%, p < 0.001). No differences were found between female diabetic patients and controls (28%, 27% vs. 40%, n.s.). CONCLUSIONS: Our study has shown a lower seroprevalence of H. pylori in diabetic patients of type I and II in comparison with the healthy population. Such finding differs from the generally accepted experience of the higher sensitivity of these patients to infection. The practical significance of the observation remains unsolved.


Subject(s)
Diabetes Mellitus/microbiology , Helicobacter Infections/complications , Helicobacter pylori/isolation & purification , Antibodies, Bacterial/blood , Female , Helicobacter Infections/diagnosis , Humans , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...